NASHUA, N.H., Oct. 16, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a world medical know-how chief offering progressive most cancers detection and remedy options, right now introduced that it’ll host a know-how innovation webinar on the present remedy panorama and unmet medical wants for treating most cancers, on Wednesday, October 21, 2020, at 10am Japanese Time.
The decision will function displays by key opinion leaders Santosh Kesari, MD, PhD, John Wayne Most cancers Heart, Janie Grumley, MD, FACS, John Wayne Most cancers Heart and Té Vuong, MD, B.Sc., Fountain Valley Regional Hospital & Medical Heart, who will talk about the present remedy panorama and new progressive strategies for treating sufferers with cancers resembling glioblastoma (GBM), breast and rectal.
iCAD’s administration group will present an replace on improvements throughout the detection and remedy companies, together with an outline of iCAD’s breast most cancers risk-assessment answer, a key ingredient within the transformation from age-based screening to risk-adaptive screening. Additionally highlighted might be just lately offered optimistic scientific information for Xoft® Mind IORT as a viable remedy choice for GBM. The administration group, together with Drs. Vuong and Santosh might be obtainable to reply questions following the formal displays.
To register for the occasion, please click on here.
Janie Grumley, MD, FACS, is the Director, Complete Breast Program, Director at Margie Petersen Breast Heart and John Wayne Most cancers Institute. She is a surgical breast oncologist who has experience in treating sufferers with breast most cancers and benign breast ailments. She makes a speciality of novel remedies resembling oncoplastic breast-conserving surgical procedure and intraoperative radiation remedy. Dr. Grumley discovered her path in her third yr of residency on the College of Southern California when she met a surgical breast oncologist who was remodeling breast most cancers care with the usage of oncoplastic surgical procedure. She was impressed by the distinction these strategies made in ladies’s lives throughout and after remedy.
Té Vuong, MD, B.Sc., obtained her M.D. from the Université de Montréal and continued her postgraduate coaching in radiation oncology on the College of Toronto and the Institut Gustave Roussy and Institut Curie in Paris, France.
She is a Professor at McGill College within the Division of Oncology, the place she additionally holds the place of Assistant Chair, Radiation Oncology. She was appointed Director, Radiation Oncology of the Segal Most cancers Centre on the Jewish Basic Hospital in August 2009.
Dr. Vuong is internationally acknowledged, notably for her experience within the remedy and analysis of rectal most cancers. Her present analysis focus is on excessive dose fee endorectal brachytherapy for sufferers with rectal most cancers. Her experience makes her a sought-after lecturer in each the educational and scientific communities. Her publications seem in internationally famend scientific journals.
Dr. Vuong conducts cutting-edge analysis within the space of colorectal most cancers. She has engaged in quite a few research all through her profession, as both the Principal Investigator or a co-participant. Her efforts have led to the event of recent radiation applied sciences and scientific protocols for the remedy of gastrointestinal most cancers.
Santosh Kesari, MD, PhD, is a board-certified neurologist and neuro-oncologist and is at present Chair and Professor, Division of Translational Neurosciences and Neurotherapeutics, John Wayne Most cancers Institute. He’s additionally Director of Neuro-oncology at Pacific Neuroscience Institute, Windfall Saint John’s Well being Heart and Windfall Little Firm of Mary Medical Heart Torrance, and leads the Pacific Neuroscience Analysis Heart at Pacific Neuroscience Institute. Dr. Kesari is ranked among the many high 1% of neuro-oncologists and neurologists within the nation, in line with Citadel Connolly Medical Ltd and an internationally acknowledged scientist and clinician. He’s a winner of an Innovation Award by the San Diego Enterprise Journal. He’s on the advisory board of American Mind Tumor Affiliation, San Diego Mind Tumor Basis, Chris Elliott Fund, Nicolas Conor Institute, Voices In opposition to Mind Most cancers, and Philippine Mind Tumor Alliance. He has been the creator of over 250 scientific publications, opinions, or books. He’s the inventor on a number of patents and patent purposes, and founder and advisor to many most cancers and neurosciences centered biotech startups. As well as, he’s a member of the Los Angeles Biomedical Analysis Institute.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a world medical know-how chief offering progressive most cancers detection and remedy options.
The Xoft® Axxent® Digital Brachytherapy (eBx®) System® is FDA-cleared, CE marked and licensed in a rising variety of nations for the remedy of most cancers wherever within the physique. It makes use of a proprietary miniaturized x-ray supply to ship a exact, concentrated dose of radiation on to the tumor website, whereas minimizing threat of harm to wholesome tissue in close by areas of the physique.
For extra data, go to www.icadmed.com and www.xoftinc.com.
Ahead-Wanting Statements
Sure statements contained on this Information Launch represent “forward-looking statements” throughout the which means of the Personal Securities Litigation Reform Act of 1995, together with statements concerning the future prospects for the Firm’s know-how platforms and merchandise. Such forward-looking statements contain plenty of identified and unknown dangers, uncertainties and different components which can trigger the precise outcomes, efficiency or achievements of the Firm to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Such components embody, however are usually not restricted, to the Firm’s skill to realize enterprise and strategic goals, the power of IORT to offer flexibility, mobility or different benefits, to be extra useful for sufferers than conventional remedy or to be accepted by sufferers or clinicians, the affect of provide and manufacturing constraints or difficulties, product market acceptance, attainable technological obsolescence of merchandise, elevated competitors, litigation and/or authorities regulation, modifications in Medicare or different reimbursement insurance policies, dangers regarding our present and future debt obligations, aggressive components, the consequences of a decline within the financial system or markets served by the Firm; and different dangers detailed within the Firm’s filings with the Securities and Trade Fee. The phrases “imagine,” “reveal,” “intend,” “count on,” “estimate,” “will,” “proceed,” “anticipate,” “doubtless,” “search,” and related expressions establish forward-looking statements. Readers are cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date the assertion was made. The Firm is beneath no obligation to offer any updates to any data contained on this launch. For added disclosure relating to these and different dangers confronted by iCAD, please see the disclosure contained in our public filings with the Securities and Trade Fee, obtainable on the Buyers part of our web site at http://www.icadmed.com and on the SEC’s web site at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Amy Prepare dinner, iCAD
acook@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
jeremy@lifesciadvisors.com
